STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe

Abstract The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) f...

Full description

Saved in:
Bibliographic Details
Published inEuropace (London, England) Vol. 25; no. 4; pp. 1284 - 1295
Main Authors Grehn, Melanie, Mandija, Stefano, Miszczyk, Marcin, Krug, David, Tomasik, Bartłomiej, Stickney, Kristine E, Alcantara, Pino, Alongi, Filippo, Anselmino, Matteo, Aranda, Ricardo Salgado, Balgobind, Brian V, Boda-Heggemann, Judit, Boldt, Leif-Hendrik, Bottoni, Nicola, Cvek, Jakub, Elicin, Olgun, De Ferrari, Gaetano Maria, Hassink, Rutger J, Hazelaar, Colien, Hindricks, Gerhard, Hurkmans, Coen, Iotti, Cinzia, Jadczyk, Tomasz, Jiravsky, Otakar, Jumeau, Raphaël, Kristiansen, Steen Buus, Levis, Mario, López, Manuel Algara, Martí-Almor, Julio, Mehrhof, Felix, Møller, Ditte Sloth, Molon, Giulio, Ouss, Alexandre, Peichl, Petr, Plasek, Jiri, Postema, Pieter G, Quesada, Aurelio, Reichlin, Tobias, Rordorf, Roberto, Rudic, Boris, Saguner, Ardan M, ter Bekke, Rachel M A, Torrecilla, José López, Troost, Esther G C, Vitolo, Viviana, Andratschke, Nicolaus, Zeppenfeld, Katja, Blamek, Slawomir, Fast, Martin, de Panfilis, Ludovica, Blanck, Oliver, Pruvot, Etienne, Verhoeff, Joost J C
Format Journal Article
LanguageEnglish
Published US Oxford University Press 15.04.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions’ experience in VT catheter ablation (83% ≥ 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Conflict of interests: D.K. has received honoraria from Merck Sharp & Dohme and Pfizer, as well as research funding from Merck KGaA, all outside of the submitted work. M.A. is a consultant for Biosense Webster and Boston Scientific, has received educational grants from Abbott, and is a proctor for Medtronic. J.B.-H. received personal fees from EBAMed SA, Switzerland, outside the submitted work. O.E. received honoraries for participation on advisory board meetings from Merck Serono, MSD, and AstraZeneca concerning oncologic treatments and also received project funding for clinical trials from non-profit organizations, all outside of the submitted work. T.R. gets research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, and the Sitem Insel support fund. Speaker/consulting honoraria or travel support from Abbott/SJM, Bayer, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, Farapulse, Medtronic, and Pfizer-BMS. Support for the institution’s fellowship programme from Abbott/SJM, Biosense Webster, Biotronik, Boston Scientific and Medtronic. A.S. received educational grants through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, BMS/Pfizer, and Medtronic; and speaker/advisory board fees from Abbott, Bayer Healthcare, Daiichi Sankyo, Medtronic and Novartis. All other authors declare no conflict of interests.
Etienne Pruvot and Joost J. C. Verhoeff co-equal last authorship.
Melanie Grehn and Stefano Mandija co-equal first authorship.
ISSN:1099-5129
1532-2092
1532-2092
DOI:10.1093/europace/euac238